



8 December 2016

## **ASX ANNOUNCEMENT**

### **Penthrox approved for sale in Taiwan**

Medical Developments International Limited (ASX: MVP) is delighted to announce it has received regulatory approval from the Taiwan Food and Drug Administration (TFDA) for Penthrox to be used for patients with trauma and associated pain and for the relief of pain in monitored conscious patients who require analgesia for surgical procedures.

Taiwan is a country of approximately 23 million people of which 1.6m patients were admitted to hospitals with trauma injuries. In addition there are 10.3m "Minor Surgical Procedures" each year.

MVP CEO, Mr. John Sharman, said: "It is significant that the approval from the TFDA is also for Minor Surgical Procedures which substantially increases the size of the market for Penthrox in Taiwan. This is because everywhere in the world we are developing our clinical program in an effort to widen the approved indications for the use of Penthrox."

The Chairman of MVP, David Williams said that "even though Taiwan is a country roughly the size of Australia, it is a sophisticated and important market for us in Asia. We think take-up will be quick and expect to see our first sales within a few weeks."

Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 3 9547 1888



### **About Pentrox**

Penthrox is a fast onset, non-opioid analgesic which is indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5 million units sold. Mundipharma International has exclusive product rights in 39 European markets (including France, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom).

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.